Carcinogenesis Advance Access published online on July 7, 2004
Carcinogenesis, doi:10.1093/carcin/bgh228
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Physiology and Pharmacology, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
* To whom correspondence should be addressed. E-mail: tiedge{at}hscbklyn.edu.
BC200 RNA, a small functional RNA that operates as a translational modulator, has been implicated in the regulation of local synaptodendritic protein synthesis in neurons. Cell-type specific expression of BC200 RNA is tightly controlled such that the RNA is not normally detected in somatic cells other than neurons. However, the neuron-specific control of BC200 expression is deregulated in a number of tumors. We report now that BC200 RNA is expressed at high levels in invasive carcinomas of the breast. In normal breast tissue or in benign tumors such as fibroadenomas, in contrast, we found that the RNA is not detectable at significant levels. The difference in expression levels between invasive carcinomas and normal/benign tissue was statistically highly significant. Receiver Operating Characteristics (ROC) analysis of sensitivity and specificity confirmed the diagnostic power of BC200 RNA as a molecular marker of invasive breast cancer. In ductal carcinomas in situ, furthermore, significant BC200 expression was associated with high nuclear grade, a result to suggest that the presence of BC200 RNA in such tumors may be used as a prognostic indicator of tumor progression. The combined results demonstrate the potential of BC200 expression to serve as a molecular tool in the diagnosis and/or prognosis of breast cancer.
Revised June 17, 2004
Accepted June 26, 2004
CANCER BIOLOGY
BC200 RNA in invasive and preinvasive breast cancer
2 Department of Surgery, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
3 Scientific Computing Center, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
4 Institute of Pathology, Heinrich-Heine-University, D-40225 Düsseldorf, Germany
5 Gerhard-Domagk-Institute of Pathology, University of Münster School of Medicine, D-48129 Münster, Germany
6 Department of Physiology and Pharmacology, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA; Department of Neurology, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. P. Mello, E. F. Abrantes, C. H. Torres, A. Machado-Lima, R. d. S. Fonseca, D. M. Carraro, R. R. Brentani, L. F. L. Reis, and H. Brentani No-match ORESTES explored as tumor markers Nucleic Acids Res., May 1, 2009; 37(8): 2607 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mus, P. R. Hof, and H. Tiedge Dendritic BC200 RNA in aging and in Alzheimer's disease PNAS, June 19, 2007; 104(25): 10679 - 10684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. Prasanth and D. L. Spector Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum Genes & Dev., January 1, 2007; 21(1): 11 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Muslimov, A. Iacoangeli, J. Brosius, and H. Tiedge Spatial codes in dendritic BC1 RNA J. Cell Biol., November 6, 2006; 175(3): 427 - 439. [Abstract] [Full Text] [PDF]
|
|